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Abstract
Like other HIV-1 (human immunodeficiency virus type 1) proteins, Tat undergoes rapid mutation and occurs in numerous sequence
variants in nature. Virus isolated from patients often has defects in Tat that lower its activity. The levels of P-TEFb, an essential cellular
cofactor for Tat, are elevated by T-cell activation. To test the hypothesis that stimulation of P-TEFb levels might compensate for attenuation
of Tat activity, we generated Tat constructs with a range of transactivation function. Transactivation by the Tat mutants correlated with their
ability to bind to P-TEFb in vitro. Treatment of U937 cells with the phorbol ester PMA (phorbol myristate acetate) induced P-TEFb and
stimulated Tat transactivation for alleles with basal transcription activity above a threshold (5% compared to wild-type). Highly active
alleles (66% of wild-type) were stimulated to a lesser extent than those with activity in the intermediate range. Thus, attenuation of Tat
function, in concert with low levels of P-TEFb activity, could serve to keep the virus in a latent state in quiescent cells yet permit viral
replication after cell activation.
© 2003 Elsevier Science (USA). All rights reserved.
Introduction
Viral latency remains an intractable problem in human
immunodeficiency virus type 1 (HIV-1) infection, and one
that is refractory to highly active antiretroviral therapy
(HAART). Understanding the contribution of latently in-
fected cells to the persistence of HIV-1 and the mechanisms
by which virus is maintained in a latent state will be critical
to the development of treatment strategies. Viral replication
can be arrested at various stages of replication, but the most
stable pool of cells contains postintegration latently infected
memory CD4 cells, which carry a transcriptionally silent
integrated form of HIV-1 (Chun et al., 1995, 1997). Reac-
tivation of these cells can lead to induction of viral tran-
scription, completion of the viral cycle, and production of
infectious particles. Studies with cells from patients and
with transformed cell line models of viral latency have
implicated the regulation of transcription by the viral pro-
tein Tat (Transactivator of transcription) and its cellular
partner P-TEFb (positive transcription elongation factor b)
as one of the molecular mechanisms responsible for postint-
egration latency (see below, and Price, 2000, for review).
During productive infection, Tat acts through the TAR
(Trans Activation Response) element in the viral long ter-
minal repeat (LTR) to control HIV-1 transcription. Tran-
scription is initiated by RNA polymerase II (pol II) at the
promoter in the viral LTR. In the absence of Tat, these
complexes are nonprocessive and terminate prematurely,
resulting in the production of short, promoter-proximal
RNAs (Kato et al., 1992; Kessler and Mathews, 1992). In
the presence of Tat, processive pol II complexes are formed
and full-length transcripts are produced (Feinberg et al.,
1991; Garcı´a-Martı´nez et al., 1995; Graeble et al., 1993;
Kato et al., 1992; Laspia et al., 1989, 1993; Marciniak and
Sharp, 1991). HIV-1 Tat is synthesized as a protein of
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72–101 amino acids (aa), and the 72-aa form is sufficient to
activate transcription from the HIV-1 promoter (Cullen,
1986; Sodroski et al., 1985). Tat72 is composed of five
functional domains, that except for the auxiliary domain,
contain multiple residues that are highly conserved. The
protein’s TAR-binding domain targets it to the TAR ele-
ment located near the 5 end of the viral transcripts; this
interaction is necessary for Tat-mediated transcription. The
three N-terminal domains of Tat, contained in the first 48 aa,
make up the activation domain; this domain is necessary for
binding to the cellular transcription elongation factor P-
TEFb.
Tat functions in HIV-1 transactivation by interacting
with P-TEFb in the elongating pol II complex (Mancebo et
al., 1997; Zhu et al., 1997). P-TEFb complexes that contain
cyclin T1, also called Tat-associated kinase (TAK), bind
directly to Tat and the cyclin-dependent kinase CDK9 (Peng
et al., 1998; Wei et al., 1998). This kinase phosphorylates
the carboxy-terminal domain (CTD) of the large subunit of
pol II, thereby facilitating the transition of pol II into a
productive elongation mode. Cyclin T1 in complex with Tat
binds to TAR. Hence, Tat serves as a bridge between the
newly synthesized TAR element and P-TEFb to facilitate
the formation of highly processive transcription elongation
complexes (for review, see Karn, 1999, and references
therein).
Several findings point to the involvement of Tat in la-
tency. Peripheral blood mononuclear cell (PBMC) samples
from patients contain integrated proviruses with defective
Tat alleles that have less than wild-type activity (Delassus et
al., 1992; Kirchhoff et al., 1997; Meyerhans et al., 1989;
Vartanian et al., 1992). Such cells produce only short viral
transcripts (Adams et al., 1994). In U1 cells, derived from
an HIV-1-infected U937 cell culture, viral transcription is
limited by a mutation in the Tat gene, resulting in a pro-
found defect in transcriptional elongation (Adams et al.,
1994; Cannon et al., 1994; Emiliani et al., 1998; Folks et al.,
1987, 1988). The integrated HIV-1 provirus in J1.1 cells
also carries a mutant Tat gene (S. Reza, M. Rosetti, M.B.
Mathews, T. Pe’ery, unpublished data), while ACH-2 cells
have a mutation in the TAR element (Emiliani et al., 1996).
PBMCs from asymptomatically infected individuals display
a similar transcriptional defect, which can be overcome
when the cells are activated in vitro or during viremia
(Adams et al., 1994; Peng et al., 1995).
P-TEFb/TAK is one of the factors induced during T-cell
activation. The phorbol ester phorbol 12-myristate 13-ace-
tate (PMA) stimulates TAK levels and activity in PBMCs
and PBLs (peripheral blood leukocytes), and also in
promonocytic cell lines (Herrmann et al., 1998; Yang et al.,
1997; and this study). Similarly, TAK is induced in resting
CD4 T lymphocytes activated with a combination of cy-
tokines (Ghose et al., 2001). In addition, freshly isolated
human primary monocytes express very low levels of cyclin
T1 and TAK activity, which increase dramatically upon
differentiation to macrophages (Liou et al., 2002). Concom-
itantly, increase in HIV-1 replication is seen in promono-
cytic cells (Okada et al., 1995) and in PBMCs (Kaufman et
al., 1987; Nabel and Baltimore, 1987) treated with phorbol
esters, as well as in cytokine-treated resting CD4 T lym-
phocytes (Chun et al., 1998).
Because the high HIV-1 mutation rate generates a large
number of Tat variants, it is possible that viruses encoding
partially defective Tat protein facilitate the establishment of
postintegration latency and serve as a source for recurrent
infection after induction of P-TEFb. A corollary of this
hypothesis is that induction of P-TEFb should ameliorate
the defects of attenuated Tat mutants. To test this conjec-
ture, we characterized a set of naturally occurring Tat mu-
tants that are impaired to varying degrees. Using PMA to
induce P-TEFb kinase activity in promonocytic U937 cells,
we examined the ability of PMA to stimulate transactivation
by crippled Tat mutants. Our data show that Tat transacti-
vation activity correlates with the strength of its interaction
with P-TEFb, and that PMA preferentially enhances the
activity of Tat mutants that are significantly impaired in
transactivation activity. In stimulated cells, the activity of
partially defective Tat mutants was restored to wild-type
levels. In addition, we conducted a statistical analysis of Tat
variation to evaluate the contribution of individual residues
to its function in transactivation. Although Tat sequences
from clinical HIV-1 isolates are highly variable in some
domains, this analysis revealed that a restricted range of
amino acid substitutions is strongly preferred.
Results
The induction of P-TEFb by phorbol esters and lympho-
kines suggested that cell activation might compensate for
Tat deficiency, thereby enabling viral replication. To test
this hypothesis, we examined the ability of PMA to enhance
the transactivation ability of a series of mutant Tat proteins
that are debilitated to varying extents.
Construction of a panel of Tat mutants
Mutations (Fig. 1) were introduced into the wild-type Tat
sequence present in the NL4-3 infectious clone (Chen et al.,
1994). This allele is identical to HXB2 Tat apart from the
substitution of methionine for isoleucine at position 39. The
139M change occurs in some natural viral isolates as dis-
cussed below and did not affect the Tat:P-TEFb interaction
as measured by TAK assays (data not shown).
Tat mutants were chosen to give a wide range of trans-
activation activities based on published data. First, as a
benchmark for the latent phenotype, we used the H13L
mutation, found in one of the HIV viruses in U1 cells. This
mutant transactivated 18% as efficiently as wild-type NL4-3
Tat in an LTR-reporter assay in Jurkat cells (Emiliani et al.,
1998). Second, a set of naturally occurring variants, WHA,
WHB, WHC, and WHD, was selected. These mutations
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were isolated from patient-derived HIV-1 strains. Their
transactivation activities, measured in H9 cells, were 60%,
40%, 90%, and 20%, respectively, relative to BRU Tat (Fig.
1; Meyerhans et al., 1989). All of these proteins contain
multiple mutations in several domains of Tat (Fig. 1). WHA
is the simplest with eight mutations. WHB and WHC each
have one additional mutation, and WHD has two different
additional mutations compared to WHA. The WHA con-
struct differs from wild-type Tat in three domains, the cys-
teine-rich, core and auxiliary domains. While a partial de-
letion of the auxiliary domain does not have a major effect
on Tat transactivation, both the core and cysteine-rich do-
mains are essential for transcriptional activity and P-TEFb
binding (Zhu et al., 1997). Since mutations in the core
domain have a strong deleterious effect on Tat function, it
seemed likely that mutations in WHA between residues 39
and 42 would be chiefly responsible for its reported low
activity. Therefore, we generated an additional mutant,
Tat39-42, containing mutations in residues 39, 40, and 42 in
an otherwise wild-type background. Finally, to extend the
range of Tat activities tested, we included three artificially
generated Tat mutations selected based on information from
site-directed mutagenesis studies. The P18A, C22G, and
C31G mutants transactivated 10%, 4%, and 20% as well as
wild-type HXB2 Tat, respectively, in HeLa cells (Rice and
Carlotti, 1990).
Interaction of Tat mutants with P-TEFb in 293 cells
To evaluate the effects of the mutations under standard
conditions, we compared the activity of the Tat mutants in
293 cells. These cells are known to express large amounts of
P-TEFb (Ramanathan et al., 2001). The interaction of Tat
with P-TEFb was assessed by using the TAK (Tat-associ-
ated kinase) assay, in which GST-Tat bound P-TEFb phos-
phorylates a CTD peptide, CTD3. All the mutations were in
the same background Tat sequence and were tested against
the parental pNL4-3 Tat as wild-type. Each mutant was
expressed as a GST fusion protein and the amount of P-
TEFb binding to the beads was measured by immunoblot-
ting and kinase assays.
As visualized in Fig. 2A, all the GST fusion proteins
Fig. 1. Tat mutants and domains. The amino acid sequence of wild-type (WT) Tat from the NL4-3 strain is shown together with its functional domains
(Kuppuswamy et al., 1989). The sequence of Tat BRU, another wild-type strain, is also shown for comparison. Apart from mutant 39–42, the Tat mutants
used in this study were selected for different levels of transactivation based on published studies.
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except GST-TatP18A were successfully expressed in E.
coli. Anti-CDK9 antibody detected CDK9 bound to GST
fusions with wild-type Tat, WHA, WHB, and Tat39–42
(Fig. 2B). The efficiency of binding to WHA was similar to
that seen with wild-type, whereas WHB bound discernibly
less well, and Tat39–42 only weakly. No binding was
detected for the other mutants. To show that the bound
CDK9 is present in an active CTD kinase, we conducted
TAK assays with results that are shown in Fig. 2C and
quantified in Fig. 2D. The kinase assay data correlate
closely with those of CDK9 binding (Fig. 2B). The activity
of the WHA mutant was very similar to that of wild-type
even though the proteins differ at eight residues. In contrast,
Tat39–42, which differs from wild-type at three residues,
has lost 76% of its TAK activity. This suggests that the
39–42 group of mutations reduces TAK activity, and that
one or more of the additional mutations in WHA (T23N,
H59P, N61D, Q63E, and A67V) compensate for this defect.
The WHB mutant had an intermediate level of TAK activ-
ity, implying that the A21D substitution is somewhat dele-
terious. The other mutants did not give any signal in the
CDK9 binding or kinase assays indicating that they contain
severely deleterious mutations, namely H13L, C22G, F38L
(in WHC), and N24K and/or V36S (in WHD).
Transactivation by Tat mutants in 293 cells
The activity of the Tat mutants was measured in an LTR-
reporter assay in 293 cells. Each Tat mutant was expressed
under the control of the Rous sarcoma virus (RSV) promoter
and the amount of the wild-type Tat expressing vector was
titrated into the linear range of the assay. Fig. 3 depicts the
degree of transactivation observed with the mutants relative to
assays lacking Tat, and the efficiency of each is also presented
relative to wild-type Tat. The results are in good agreement
with those from the TAK assay, with the proviso that the
transactivation assay is more sensitive and consequently al-
lowed discrimination among severely defective mutants. The
transactivation activity rank order was as follows: wild-type
WHA  WHB  Tat39-42  WHD  WHO  H13L 
P18A  C31G  C22G (the activity of the C22G mutant
being only slightly above background). These results show that
the panel of mutants selected for this study express a wide
range of activity, and confirm that their transactivation effi-
ciencies correlate with their ability to bind P-TEFb.
Induction of P-TEFb by PMA
Treatment with the phorbol esters PMA or phytohemag-
glutinin (PHA) can induce P-TEFb kinase activity in
Fig. 2. Effect of Tat mutations on P-TEFb binding from 293 cell extract. (A) Equal amounts of GST-Tat wild-type and mutant proteins were immobilized
on glutathione-Sepharose beads, separated in an sodium dodecyl sulfate–polyacrylamide gel, and visualized with Coomassie Brilliant Blue stain. (B and C)
The GST-Tat beads were incubated with equal amounts of 293 cell S100 extract and the bound protein detected by immunoblotting with anti-CDK9 antibody
(B) or assayed for P-TEFb kinase (TAK) activity (C). (D) The kinase assays were repeated twice and CTD3 phosphorylation was quantified by using a
phosphorimager (Amersham). The average values, with standard error, are expressed relative to the activity of wild-type Tat.
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promonocytic U937 cells, the parental line from which U1
cells were derived. Kinase activity is also inducible in HL60
cells, another myeloid cell line. Furthermore, P-TEFb levels
are induced in activated primary lymphocytes (Garriga et
al., 1998; Herrmann et al., 1998). To determine whether this
phenomenon extends to lymphoid cell lines, we examined
the effect of PMA on P-TEFb activity in two T-cell lines,
CEM and Jurkat cells. These cells, as well as U937 cells,
were treated with PMA for 24 h and harvested for prepara-
tion of whole-cell extracts. P-TEFb kinase activity was
assayed after binding to GST-Tat, using the TAK assay. Fig.
4A shows that basal P-TEFb activity varied widely among
the three different cell lines. Untreated Jurkat and CEM
cells had substantial P-TEFb activity, whereas U937 cells
exhibited very low levels of activity that were detectable
only with larger amounts of cell extract. As reported previ-
ously, treatment of U937 cells with PMA gave a significant
induction of P-TEFb activity (maximally 50-fold at 5 ng/ml;
Fig. 4B). Induction was also seen in Jurkat cells, where
kinase activity peaked at a PMA concentration of 0.5 ng/ml
but declined at higher concentrations. In CEM cells, how-
ever, PMA caused a reduction in kinase activity as seen
previously (Yang et al., 1997), which was partially restored
at higher concentrations.
U937 cells were selected for further study because they
gave the greatest response to PMA. The induction of P-
TEFb activity displayed a biphasic time course in U937
cells treated with PMA at 5 ng/ml (Fig. 4C). An early phase
of induction at 3–6 h was followed by a second phase that
peaked at 24 h. Elevated kinase activity persisted at least to
48 h albeit at a lower level. Such kinetics are not unexpected
since induction by PMA of several enzyme systems is often
biphasic (Rostaing et al., 1999). In keeping with our trans-
fection protocol, subsequent experiments employed treat-
ment with PMA at 5 ng/ml for 24 h.
The induction of P-TEFb activity was accompanied by
increased levels of its kinase subunit, CDK9 (Fig. 4D). In
addition to P-TEFb, several other kinases can phosphorylate
the CTD, and some studies have suggested that CDK7
kinase complexes associate with Tat and phosphorylate the
CTD (Garcı´a-Martı´nez et al., 1997). To verify that our
kinase assays specifically detected the induction of P-TEFb,
we measured the levels of CDK7, CDK8, and CDK9 in
untreated and PMA-treated U937 cell extracts by immuno-
blotting. All three kinases, as well as cyclin T1, were in-
duced by PMA (Fig. 4E, lanes 1 and 2). However, only
CDK9 and cyclin T1 bound to GST-Tat (lanes 3 and 4). An
actin immunoblot was used to verify that protein loading
Fig. 3. Tat transactivation in 293 cells. Tat transactivation was measured in 293 cells by cotransfection of 0.1 g of the appropriate Tat-expressing plasmid
or empty vector with 0.4 g of HIV-1 LTR-luciferase reporter and 2 g of a renilla luciferase transfection control vector. Assays were performed in duplicate
and the average relative luciferase activity (firefly:renilla) is depicted for each Tat mutant. Values relative to wild-type Tat are shown at the bottom of the
chart. WT, wild-type; HIV-1, human immunodeficiency virus type 1; LTR, long terminal repeat.
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was equal in treated and untreated lanes. To rule out the
possibility that these results are due to the instability of
cyclin T1 and CDK9 in extracts of untreated U937 cells,
cells were lysed in denaturing conditions by boiling in an
sodium dodecyl sulfate (SDS)-containing buffer. No signif-
icant difference was observed between extracts prepared in
standard conditions (WCL buffer) or denaturing conditions
(SDS buffer), and PMA induction of cyclin T1 and CDK9
was clearly observed in both cases (Fig. 4F). In our hands,
there was no substantial pool of P-TEFb that is refractory to
extraction by non-ionic detergents (Martin-Serrano et al.,
2002). We conclude that both components of P-TEFb are
induced by PMA treatment of U937 cells.
Activity of Tat mutants in U937 cells
TAK assays were conducted to substantiate the binding
of P-TEFb from U937 cells to the Tat mutants. Extracts
from unstimulated U937 cells have very little P-TEFb (Fig.
4), so the cells were first treated with PMA for 24 h to
induce P-TEFb. Equal amounts of whole-cell extract was
used in a TAK assay with the GST-Tat mutants. Fig. 5
displays the expression of the GST-Tat mutants and the
results of kinase assays using PMA-treated U937 extracts.
As with 293 extracts, wild-type Tat and WHA gave nearly
identical activities, 100% and 96%, respectively; Tat39–42
and WHB were less active; and the remaining mutants did
Fig. 4. Induction of P-TEFb by phorbol 12-myristate 13-acatate (PMA). (A) Induction of P-TEFb activity varies among different cell lines. CEM, Jurkat, and
U937 cells were treated for 24 h with 0.5, 1, 5, 10, or 20 ng/ml PMA. Whole-cell extracts (400 g of total protein) were assayed for P-TEFb kinase (TAK)
activity. (B) Quantitation of kinase activity in U937 cells treated with increasing amounts of PMA for 24 h. The results of the kinase assay shown in the
bottom panel in A were quantitated by using an Instant Imager (Perkin-Elmer Corp.). (C) Time course of P-TEFb kinase activity induction in U937 cells
treated with 5 ng/ml PMA. (D) Induction of CDK9 in U937 cells treated with PMA. Cells were incubated in either 0, 0.5, or 5 ng/ml PMA for 24 h, whole-cell
extract was prepared and immunoblotted by using anti-CDK9 antibodies. (E) Cyclin T1 and CDK9 induction by PMA and binding to GST-Tat. Extracts were
prepared from control U937 cells and cells treated with 5 ng/ml PMA for 24 h. Immunoblots with antibodies against cyclin T1, CDK9, CDK7, CDK8, and
actin were carried out on the cell extracts (lanes 1 and 2) or proteins bound to GST-Tat72 (lanes 3 and 4). Also shown is the GST-Tat72 protein bound to
glutathione-Sepharose beads, detected by staining with Coomassie Brilliant Blue. (F) CyclinT1 and CDK9 levels in U937 cell extracts prepared in different
ways. Extracts were prepared from control U937 cells or cells treated with 5 ng/ml PMA for 24 h by lysis in denaturing (Sodium dodecyl sulfate) or
nondenaturing (EBCD) conditions. Immunoblots were probed with antibodies against cyclin T1, CDK9, and actin. Increased loading of the gel relative to
that shown in Fig. 4E allowed the detection of cyclinT1 and CDK9 in untreated cells.
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not register significant kinase activity in these assays. It is
notable, however, that Tat39–42 was substantially stronger
in this assay (52% of wild-type) than in 293 cells (24%; Fig.
2D). This discrepancy may reflect uncertainties inherent in
quantitation of weakly active mutants in the kinase assay, or
it may be due to differences between the two cell types or to
the treatment of the U937 cells with PMA.
PMA treatment of U937 cells enhances Tat
transactivation
We assumed that induction of P-TEFb levels would
increase the ability of attenuated Tat variants to transacti-
vate expression from the HIV-1 promoter. To test this
premise, we measured the activity of Tat H13L derived
from latently infected U1 cells. The data of Fig. 6A and B
confirm that transactivation of the HIV LTR was enhanced
by treatment with PMA, and that the experimental param-
eters of concentration and time developed for P-TEFb in-
duction (Fig. 4) were suitable for examining Tat transacti-
vation. Note that there was no distinct peak of expression at
3–6 h, in contrast to the transient peak of P-TEFb seen in
Fig. 4C; presumably this is because insufficient time has
elapsed for the increased P-TEFb activity to be registered in
terms of luciferase transcription and translation.
To choose a suitable promoter for our effector and trans-
fection control plasmids (Tat and renilla luciferase), we
compared the activity of the Simian virus (SV40), Cyto-
megalovirus immediate early (CMV), and RSV promoters
in unstimulated and stimulated U937 cells. Both CMV and
RSV promoters are active in unstimulated cells (Fig. 6C),
but the CMV promoter is induced over 2.5-fold after PMA
stimulation compared to the RSV promoter, which is in-
duced less than 1.4-fold. The differential sensitivity of these
two promoters to PMA has been documented previously
(Stein et al., 1993). Hence, the RSV promoter was selected
to avoid significant induction of Tat and renilla expression
by PMA. Tat transactivation was increased about 3-fold by
PMA treatment over a wide range of RSV-Tat amounts in
both the linear and saturating regions of the dose-response
curve (Fig. 6D). For subsequent experiments, we used 1 g
of RSV-Tat plasmid, which lies in the middle of the linear
range of the concentration curve to ensure that the results
would not be affected by mild perturbations in Tat expres-
sion from the RSV promoter.
Differential stimulation of Tat mutants by PMA
The ability of PMA induction to rescue Tat transactiva-
tion by the various Tat mutants was assessed in U937 cells.
Since induction of P-TEFb by PMA peaked at 3–6 h and
then again at 24 h of treatment while luciferase reporter
activity peaks at 12–18 h after transfection (data not shown),
the phorbol ester-stimulated cells were pretreated for 12 h
with PMA, then transfected and cultured for another 12 h
with PMA before harvesting for luciferase activity measure-
ment. Data are expressed relative to the activity of wild-type
Tat in the absence of PMA treatment.
As shown in Fig. 7A, the relative transcriptional activi-
ties of the Tat mutants in unstimulated U937 cells were
Fig. 5. Binding of P-TEFb from U937 cells to Tat mutants. (A) Equal amounts of GST-Tat mutants were immobilized on glutathione-Sepharose beads
visualized with Coomassie Brilliant Blue stain. (B) Whole-cell extract was prepared from U937 cells treated with 5 ng/ml PMA for 24 h and equal amounts
of extract were incubated with the GST-Tat beads. P-TEFb kinase (TAK) assays were carried out with CTD4 substrate and the phosphorylation of CTD4
was visualized by gel electrophoresis and autoradiography. (C) The extent of CTD4 phosphorylation in two kinase assays was quantified on a phosphorimager
(Amersham) and expressed as a ratio to the activity of wild-type Tat. Average values and standard error are shown. WT, wild-type.
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similar to those seen in 293 cells (Fig. 3). When the cells
were stimulated by PMA there was an increase in the
activity of all the mutants except for the weakest ones,
namely P18A, C22G, and C31G. The degree of stimulation
was not uniform, however. For mutants in the intermediate
range of activity (Tat39–42, WHD, WHC, and H13L), the
degree of induction was considerably greater after PMA
treatment. For the mutants with the highest basal activities
(WHA and WHB), the induced activities approached that of
wild-type. This suggests that the induced activity has a limit
that cannot be exceeded.
These differences are better visualized when the ratio of
induction of transactivation by PMA for each mutant is
plotted against its basal transactivation activity (without
PMA) relative to wild-type Tat (Fig. 7B). At the left end of
the chart are mutants P18A, C22G, and C31G, which have
very low levels of basal activity (5% of wild-type); for
these mutants, treatment with PMA gave little or no increase
in activity, resulting in an induction ratio close to 1. At the
other extreme, mutants WHA and WHB have higher basal
levels of activity, approaching that of wild-type Tat; their
induction ratios were close to 3. In the middle ground are
four mutants, WHC, H13L, WHD, and Tat39-42, with low
to intermediate basal activities, ranging from 11% to 42%
relative to wild-type; PMA elicited a substantial increase in
the activity in these mutants, with induction ratios from 4.7
to 7.1. Thus, the Tat mutants can be divided into three
groups with respect to their transactivation activity. Those
Fig. 6. Stimulation of Tat H13L transactivation in U937 cells by PMA treatment. (A) Time course of reporter expression in phorbol 12-myristate 13-acetate
(PMA)-treated U937 cells. Cells were transfected with 1 g of Tat H13L-expressing plasmid together with 4 g of human immunodeficiency virus type 1
(HIV-1) long terminal repeat (LTR)-luciferase reporter and 7 g of renilla luciferase control, and were incubated in the presence of 5 ng/ml PMA for 24 h.
Results shown are the ratios of firefly to renilla luciferase activities averaged over three experiments. (B) Effect of PMA concentration on reporter expression.
Cells were transfected as in A, incubated for 24 h in the presence of various concentrations of PMA, then harvested for luciferase assay. (C) Effect of PMA
treatment on reporter expression from different promoters. U937 cells were transfected as in A with 10 g of pSV40-Lac, pRSV-Lac, or pCMV-Lac, or were
mock transfected (blank). Cells were incubated in 0 or 5 ng/ml PMA for 24 h and -galactosidase activity (Ausubel et al., 1991) was assayed with 100 g
of lysate. The fold increase in activity after PMA treatment for each promoter is shown. Results are the average of two experiments. (D) Effect of increasing
amounts of RSV-Tat plasmid on PMA induction of HIV LTR activity. U937 cells were pretreated for 12 h with 0 or 5 ng/ml PMA before transfection, then
incubated for an additional 12 h in the same concentrations of PMA. Transfection was carried out with 4 g of HIV-1 LTR-luciferase reporter and 7 g of
renilla luciferase control in addition to 0, 0.6, 1.5, 3, 6, or 9 g of RSV-Tat. Cells were harvested and the results of the dual luciferase assay are shown. Results
are the average of two samples.
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with very low activity are essentially insensitive to PMA
induction, those with high activity are mildly induced
(about 3-fold), and those with intermediate activity are
stimulated to the greatest degree (about 6-fold) by PMA
treatment. In the presence of PMA, the function of Tat
mutants with low to intermediate basal activities was
boosted to at least 60% of the basal activity of wild-type
Tat, which might be sufficient to allow escape from latency.
Fig. 7. Effect of Tat mutations on transactivation in U937 cells. (A) U937 cells were pretreated for 12 h with 0 or 5 ng/ml phorbol 12-myristate 13-acetate
(PMA) before transfection, then incubated for an additional 12 h in the same concentrations of PMA. Transfection was carried out with 1 g of Tat-expressing
plasmid together with 4 g of HIV-1 LTR-luciferase reporter and 7 g of renilla luciferase control. Relative luciferase activities (firefly:renilla) are
normalized to the values obtained with wild-type (WT) Tat in untreated cells. Results shown are the average of two experiments. PMA-treated and untreated
cells transfected with vector alone had less than 0.5% activity of untreated wild-type Tat. (B) The induction for each Tat allele was calculated as a ratio of
the PMA-treated and untreated luciferase values from panel A. The basal activity for each allele is defined as its transactivation activity as a percentage of
wild-type Tat transactivation, both in the absence of PMA. The fold induction values are shown next to the corresponding data point.
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Discussion
We investigated whether the low levels of intrinsic Tat
activity that are characteristic of many natural viral se-
quences can permit significant transcriptional activation in
cells after induction of P-TEFb activity. To this end, we
evaluated several cell lines commonly used to propagate
HIV-1 to determine if they mimic the modulation of P-
TEFb activity seen in primary lymphocytes and monocytes.
Our data show that promonocytic U937 cells retain this
feature, while Jurkat and CEM T-cell lines do not; the U937
cells exhibit a concentration-dependent induction of
P-TEFb with PMA treatment. We then assessed the trans-
activation ability of a series of Tat mutants in U937 cells as
well as human 293 embryonic fibroblasts. The Tat proteins
encompass a wide range of affinity for P-TEFb, and their
transactivation abilities correlated well with their P-TEFb
affinities in both cell types. In PMA-stimulated U937 cells,
the induction of P-TEFb had variable effects on the Tat
mutants, depending on the severity of the Tat defect. Severe
impairment of Tat activity eliminated PMA-driven LTR
activation, and high levels of Tat function permitted a lim-
ited increase in LTR activity after PMA treatment. Notably,
Tat alleles, which display intermediate activity in 293 cells
and unstimulated U937 cells, are stimulated to a greater
extent by PMA treatment. This finding is consistent with the
idea that attenuation of Tat activity contributes to viral latency.
Transactivation activity of Tat variants
Tat proteins with the single substitutions P18A, C22G,
and C31G were very defective in Tat transactivation (5% or
less of wild-type activity) in both 293 and U937 cells. The
C22G substitution has the most severe consequences and
abolishes Tat transactivation in a number of cell lines (Rice
and Carlotti, 1990). Since it is defective in binding to
P-TEFb, it is used as a negative control in Tat transactiva-
tion and P-TEFb binding assays (Ramanathan et al., 1999;
Zhu et al., 1997). In contrast to our results, however, Tat
P18A and C31G have been reported to retain 10% and 20%
of wild-type activity, respectively, when assayed in HeLa
cells (Rice and Carlotti, 1990). The H13L substitution al-
lowed for 10–15% of wild-type activity in 293 and U937
cells, compared to less than 20% of wild-type activity in
Jurkat cells (Emiliani et al., 1998). Such variations in the
activity of different Tat mutants depending on the cell line
have been noted (Verhoef et al., 1997), and differences
among the wild-type Tat proteins used as reference stan-
dards, may also contribute.
The four natural Tat variants that we selected from
PMBCs and virus isolates from an HIV-1-infected individ-
ual (Meyerhans et al., 1989) displayed varied Tat transac-
tivation activities. WHA and WHB, which were the most
frequent forms identified in the isolates, showed 80% and
50–65% of wild-type activity, respectively, in our cell
lines, compared to 60% and 40% in H9 cells (Meyerhans et
al., 1989). The less frequently isolated forms, WHC and
WHD, were significantly less active (11% and 27% of
wild-type); the activity of WHD was consistent with the
reported 20%, but the transactivation activity of WHC was
much lower than the 90% value reported previously, for
reasons that are not clear. All four of these natural variants
share a set of substitutions in positions 39, 40, and 42.
Introduction of these residues into a wild-type background
resulted in a Tat protein (Tat39–42) that is more defective
than WHA, which contains four additional substitutions in
the auxiliary domain and a further substitution in the cysteine-
rich domain (Fig. 1A). This observation implies that one or
more of these additional changes compensates for the dele-
terious effect of the changes in residues 39–42 (see below).
Substitutions in natural Tat variants
To gain insight into the nature and frequency of naturally
occurring substitutions in Tat from multiple virus isolates,
we analyzed the sequences of all the Tat proteins in the Los
Alamos HIV Sequence Database. The sequences were
aligned and the occurrence of each amino acid at every
position in the alignment was counted. These results are
tabulated in Fig. 8A, which shows the amino acids present
at each position and their frequencies. Based on this infor-
mation, we constructed a consensus sequence containing the
most predominant residues (Fig. 8B). Conserved residues
without alternatives are shown in white letters on black
background and conserved residues with alternatives that
occur at a significant prevalence are listed.
Overall, the most conserved domain is the core domain,
as expected. This is also highly conserved sequence among
lentivirus Tats (Garvey et al., 1990; Herrmann and Rice,
1995). In addition, many amino acids in the acidic, cysteine-
rich, and TAR-binding domains are conserved without al-
ternates. These include the six cysteines in the cysteine-rich
domain, which is essential for binding to P-TEFb, lysines
28, 50 and 51, which can be acetylated, and arginine and
lysine residues in the RNA binding domain/nuclear local-
ization sequence (Kiernan et al., 1999; Ott et al., 1999; Siomi
et al., 1990). In several cases (shown by black triangles in Fig.
8B), it has been shown that substitution of these conserved
residues results in loss of function. The auxiliary domain and
the second exon are the least conserved regions, although H65
and Q66 in the auxiliary domain are highly conserved, as
are Q72, T82, K88, K89, V91, and D98 in the second exon.
The functions of these residues are not well understood.
Correlation of Tat substitutions with activity
The NL4-3 Tat, used as wild-type in our study, departs
from the consensus in 13 of 72 positions, of which the
majority (7 of 13) are in the auxiliary domain. In most
instances, the changes consist of replacements with com-
mon alternates. The two exceptions are alanine instead of
glycine-42 and histidine instead of proline-59. Although
150 S.M. Reza et al. / Virology 310 (2003) 141–156
they have not been explicitly tested, these alterations of
conserved residues are evidently well tolerated.
The WH series of natural variants has three substitutions
between residues 39 and 42. One of these restores the
consensus glycine-42, while those at residues 39 and 40 are
at variable positions and the replacements are common
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alternates. When tested as a group, they reduce Tat activity
to about 40% of wild-type (Figs. 3 and 7A). WHA has the
highest activity (80% of wild-type) of the natural variants
tested and is the most frequent form in the virus isolates
(Meyerhans et al., 1989). It carries five additional substitu-
tions relative to the NL4-3 wild-type, one or more of which
must be compensating for the reduction brought about by
the 39–42 mutations. The asparagine for threonine change
at position 23 is a good candidate because it is in the
cysteine-rich domain and represents a common alternate.
Recent studies show that asparagine-23 increases Tat activ-
ity by 3–5 fold (Syed M. Reza, Lin-Ming Shen, Rupa
Mukhopadhyay, Mihaela Rosetti, Tsafi Pe’ery, and Michael
B. Mathews, submitted).
WHB is slightly less active than WHA (60% of wild-
type) and has an additional substitution, A21D, which is
presumably responsible for its reduced activity. This posi-
tion is relatively highly conserved although proline is found
as an alternate. In WHC, the change of the highly conserved
F38 to L reduces its activity significantly (to 10% of
wild-type), making it the least active Tat in the natural
isolates. Changing this phenylalanine to alanine reduced Tat
activity to 3% of wild-type in HeLa cells (Rice and Carlotti,
1990), whereas substitution with tryptophan, another aro-
matic amino acid, was somewhat less deleterious (40% of
wild-type activity) (Verhoef et al., 1997). The additional
changes in WHD (compared to WHA), N24K, and V36S
are in nonconserved amino acids. While K24 is almost as
common as N in this position (Fig. 8A), serine in position
36 is not an alternate suggesting that it could be the cause of
its reduced activity (25% of wild-type).
Variable stimulation by PMA
The Tat mutants tested in this study fell into three groups
with respect to their response to PMA stimulation. Treat-
ment of U937 cells with PMA increases the levels of P-
TEFb and CDK7 (Fig. 4) and possibly of other factors such
as Tat-SF1 (Zhou et al., 1998), CBP/p300 (Hottiger and
Nabel, 1998) (Benkirane et al., 1998), and NFB (West et
al., 2001) that increase transactivation of the HIV-1 LTR.
Although such factors may participate in the overall re-
sponse to PMA, P-TEFb is directly implicated as the pivotal
factor mediating the transcriptional response to Tat. Re-
duced P-TEFb levels (Liou et al., 2002) or activity (Garber
et al., 2000; Hoque et al., 2003; Mancebo et al., 1997) are
correlated with reduced Tat transactivation and viral repli-
cation, while increased formation of Tat:P-TEFb complexes
leads to increased Tat transactivation (Garber et al., 1998).
The most defective Tat mutants (P18A, C22G, and C31G)
did not respond to the increase in P-TEFb that can enhance
Tat transactivation, most probably because their binding
affinity to P-TEFb is extremely low. The activity of wild-
type Tat and mutants in the second group (WHA and WHB)
was stimulated 3-fold after PMA treatment. Mutants in
the third group, which have intermediate Tat activity, were
stimulated the most.
Despite increased levels of P-TEFb, it appears that other
factors are limiting for transactivation when Tat activity is
high. The limiting factors could be cellular components of
the transcription system, or viral elements such as TAR.
Although Tat is able to bind to TAR on its own, the binding
is promoted by cyclin T1 (Wei et al., 1998; Wimmer et al.,
1999). Binding of Tat to P-TEFb also enhances the auto-
phosphorylation of CDK9 (Garber et al., 2000), and this
increases both the binding of TAR to Tat:P-TEFb and the
phosphorylation of CTD by CDK9. Thus, the formation of
a Tat:TAR:P-TEFb complex is a cooperative process. By
virtue of their increased binding to P-TEFb, the more active
Tat molecules will also have higher affinity for TAR. Con-
sequently, TAR may become limiting as the affinity of a Tat
molecule to P-TEFb increases.
The Tat alleles WHC, WHD, 39–42, and H13L, which
display intermediate activity, might not saturate the LTR
since they have weaker binding to P-TEFb such that P-
TEFb remains the limiting factor. This hypothesis can ac-
count for the peak in the curve shown in Fig. 7B. Very weak
Tat alleles evince no LTR activation because the amount of
Tat:P-TEFb complex is the limiting factor. As Tat binding
to P-TEFb increases, the amount of Tat:P-TEFb:TAR com-
plex increases rapidly, reaching a peak at the activity of
H13L. With higher levels of Tat activity, the availability of
the TAR ligand becomes saturated and the amount of Tat:
P-TEFb:TAR complex becomes the limiting factor.
Fig. 8. Amino acid substitutions in natural human immunodeficiency virus type 1 (HIV-1) Tat alleles. Tat sequence alignment was obtained from the Los
Alamos HIV Database (http://hiv-web.lanl.gov) with 134 unique HIV sequences. (A) Frequency table. For every position in the sequence the occurrence of
each amino acid was counted and is shown in each row of the table. The 20 amino acids are arranged in the top header row by chemical classification. Cells
in the table are shaded according to the number of times an amino acid occurs at that position in the alignment: black cells, conserved residues that occur
more than 90 times (67%); gray, intermediate frequency (7–67%); white, residues that occur less than 10 times (7%). The  symbol indicates a gap in
the alignment. (B) Tat sequence variation. The frequency information was used to compile a consensus sequence, which is shown-immediately under the
assigned domains in Tat. The consensus consists of the amino acids that occur most frequently at each position in the alignment. Residues are coded according
to the degree of conservation: black and gray background, conserved (67%); white background, not conserved (67%). Within the conserved category,
positions in which no other amino acid occurred 7% of the time were classified as “conserved without alternates” and are shown in uppercase letters on
a black background, whereas positions in which one or more residues also occurred 7% of the time were classified as “conserved with alternates” and are
shown in lowercase letters on a gray background. Listed as alternates are common variations (occurring 7% of the time), shown in descending frequency
of occurrence. Substitutions observed at a frequency of7% are not displayed. Positions marked with a black triangle are known to be critical for Tat function
from previous experimental studies.
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Implications for latency
That the allele H13L exhibits the highest fold induction
after PMA treatment (Fig. 7B) suggests that the U1 provirus
is well adapted to function in U937 cells and is consistent
with the derivation of the U1 cell clone by selection of
HIV-infected U937 cells for a latent phenotype. This Tat is
able to support viral replication in U1 cells and Jurkat cells
after stimulation with TNF (tumor necrosis factor-)
(Emiliani et al., 1998; Kinter et al., 1990). These results
suggest that, at least in U937 cells, and possibly in primary
T-cells, attenuation of Tat activity can serve as a mechanism
of latency. Two other naturally occurring Tat molecules,
WHC and WHD, had low activity similar to that of the U1
Tat and could be rescued to wild-type or near wild-type
levels after PMA stimulation of U937 cells. Although it is
not known whether these Tat variants show latent behavior,
since Tat variants with a wide range in activity are gener-
ated during the course of infection, it is likely that some of
these have the right level of activity to be selected for
latency in primary lymphocytes.
In conclusion, analysis of Tat transactivation activity and
Tat:P-TEFb interactions may be useful in predicting the
potential of viruses for inducing latency in primary T cells.
Viruses with defective Tat are constantly produced by the
high level of reverse transcriptase error-prone DNA synthe-
sis and are part of the quasi-species populations of HIV-1 in
infected individuals. Cells harboring such viruses will pro-
duce low levels of viral proteins and hence escape immune
surveillance, and their continued propagation in patients
may be explained by the induction of P-TEFb and other
factors in certain cells. Depending on the level of cell
activation in response to outside stimuli and the levels of
P-TEFb in the cells, latent viruses could replicate and infect
other cells, and their high mutation rate would lead to the
reemergence of wild-type viruses. Possibly severe muta-
tions like H13L respond to a maximal cell stimulation while
less defective Tats may allow viral replication with less than
maximal P-TEFb induction. The selection for defective Tats
that lead to latency in cells with low activation levels may
represent an advantage for the preservation of the virus in
the host. We therefore speculate that one selective force
operating during HIV infection favors Tat variants with
optimal activity for maintaining a latent phenotype.
Materials and methods
Materials
Nucleoside triphosphates were purchased from Amer-
sham Biosciences (Uppsala, Sweden), and [32P]ATP was
from ICN Pharmaceuticals Inc. (Costa Mesa, CA) CTD3
(Zhu et al., 1997) and CTD4 (three and four repeats of the
heptamer YSPTSPS, respectively) peptides were synthe-
sized at the New Jersey Medical School Molecular Re-
source Facility with an ABI 433A synthesizer and purified
by high-pressure liquid chromatography on a C18 column.
The anti-CDK7, anti-CDK8, anti-CDK9, and anti-cyclinT1
affinity-purified polyclonal antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Anti-actin
monoclonal antibody was from Bio-Rad (Hercules, CA).
PMA (phorbol 12-myristate 13-acetate) was purchased
through Sigma-Aldrich (St. Louis, MO).
Cell lines and tissue culture
All cell lines were obtained from ATCC (Manassas,
VA). Suspension cultures of U937, CEM, and Jurkat cells
were maintained in RPMI (Roswell Park Memorial Insti-
tute) 1640 medium (Invitrogen Life Technologies, Carls-
bad, CA) supplemented with 2.05 mM L-glutamine and 10%
fetal bovine serum (FBS; Sigma-Aldrich). Human 293 cells
were maintained in DME-M (Dulbecco’s modified Eagle
medium) high glucose medium (Invitrogen Life Technolo-
gies), supplemented with L-glutamine, pyridoxine hydro-
chloride, and 10% FBS.
Primers
All primers were custom synthesized by Operon Tech-
nologies (Alameda, CA). Primer sequences are listed from
5 to 3 with engineered restriction sites in boldface:
pTAT3Not, CAG GGC GGC CGC GGT CCA CAC AAC
TAT; pGST5Bam, ATT CGT GGA TCC ATG GAG CCA
GTA GAT CC; pGST3Eco, TGT ACT GAA TTC TGC
TTT GAT AGA GAA AC; pRSVSpe, ATT CGT ACT
AGT ATG GAG CCA GTA GAT CC; pRLSpe, ATG ACT
AGT ATG ACT TCG AAA GTT TAT GAT CC; pRLNot,
CTT AGC GGC CGC TTA TTG TTC ATT TTT GAG;
pH13L53, GGA AGT TAC CAG GAA GTC AG;
pH13L35, TGG TAA CTT CCA GGG CTC TA; pP18A53,
AGG AAG TCA GGC TAA AAC TG; pP18A35, CAG
TTT TAG CCT GAC TTC CT; pA21D53, GCC TAA AAC
TGA CTG TAA CAA TTG C; pA21D35, GCA ATT GTT
ACA GTC AGT TTT AGG C; pC22G53, AAA CTG CTG
GAA CCA ATT GC; pC22G35, TTG GTT CCA GCA GTT
TTA GG; pT23N53, AAA CTG CTT GTA ACA ATT GC;
pT23N35, TTG TTA CAA GCA GTT TTA GG; pN24K53,
GCT TGT AAC AAG TGC TAT TGT AAA AAG TGT
TGC; pN24K35, GCA ACA CTT TTT ACA ATA GCA
CTT GTT ACA AGC; pC31G53, GCT ATT GTA AAA
AGT GTG GAT TTC ATT GCC; pC31G35, GGC AAT
GAA ATC CAC ACT TTT TAC AAT AGC; pV36S53,
GCT TTC ATT GCC AAT CCT GTT TCA CC; pV36S35,
GGT GAA ACA GGA TTG GCA ATG AAA GC; pF3853,
GCC AAG TTT GTC TGA CCA AGA AGG G; pF3835,
CCC TTC TTG GTC AGA CAA ACT TGG C; p394253,
TTT CAC CAA GAA GGG ATT AGG CAT C; p394235,
ATC CCT TCT TGG TGA AAC AAA CTT G; p596353,
CCT CAG GAC AGT GAG ACT CAT CAA G; p596335,
GCT TCT CGA GGA GTC CTG TCA CTC T; pA67V53,
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CTC ATC AAG TTT CTC TAT CAA AGC; pA67V35,
CTG AGT AGT TCA AAG AGA TAG TTT.
Plasmids and mutagenesis
The HIV infectious molecular clone pNL4-3-LucE was
kindly provided by B.K. Chen and D. Baltimore (Chen et
al., 1994). The plasmid was digested by SalI and BamHI and
the 2.6 Kb tat-rev-env fragment ligated into the same sites
in pUC19 vector (Yanisch-Perron et al., 1985). Site-specific
mutations were introduced into the resulting vector
(pUC19-Tat) using the Quickchange Site Directed Mu-
tagenesis Kit (Stratagene, La Jolla, CA). The following
sense-antisense primer pairs were used to create the corre-
sponding mutations: H13L, pH13L53/pH13L35; P18A,
pP18A53/pP18A35; A21D, pA21D53/pA21D35; C22G,
pC22G53/pC22G35; T23N, pT23N53/pT23N35; N24K,
pN24K53/pN24K35; C31G, pC31G53/pC31G35; V36S,
pV36S53/pV36S35; F38L, pF38L53/pF38L35; 3942,
p394253/p394235; 5963, p596353/p596335; A67V,
pA67V53/pA67V35. The mutations WHA, WHB, WHC,
and WHD were constructed by introducing each mutation
sequentially. The sequence of each tat gene was confirmed
by sequencing. For construction of glutathione-S-trans-
ferase (GST)-Tat fusion protein the tat gene in pUC19-Tat
was amplified by polymerase chain reaction (PCR) using
the primers pGST5Bam and pGST3Eco, purified PCR prod-
uct was digested with BamHI and EcoRI and ligated into the
same sites in pGEX2T vector (Invitrogen Life Technolo-
gies). For expression of Tat in mammalian cells under
control of the RSV promotor the tat gene was subcloned
from pUC19-Tat by PCR with primers pRSVSpe/pTat3Not,
digested with Spel and Notl and inserted into the same sites
in pRc-RSV (Invitrogen Life Technologies). The plasmid
pRSV-Renilla was constructed by PCR amplification of
renilla gene in pRL-CMV (Promega, Madison, WI) with the
primers pRLSpe and pRLNot, digestion and ligation into
SpeI and NotI sites in pRc-RSV. The plasmid pLTR-Lucif-
erase was a gift of D. Price. The plasmids pSV40-Lac,
pRSV-Lac and pCMV-Lac were a gift of S. Christakos.
Preparation of cell extracts
Cytoplasmic extracts of 293 cells were made by the
Dignam method (Dignam et al., 1983). Whole-cell extracts
from U937, CEM, and Jurkat cells were prepared by brief
sonication of harvested cells in Whole Cell Lysis buffer
[WCL; Tris-Cl, pH 8.0, 50 mM, NaCl 120 mM, Nonidet
P-40 (NP-40) 0.5%, dithiothreitol (DTT) 500 nM, MgCl2 4
mM] followed by centrifugation at 10,000  g to clear the
lysate. Extract from PMA-treated U937 cells was prepared
from cells maintained in RPMI 1640 with glutamine, 10%
FBS, and PMA for 24 h. Addition of PMA causes cells to
become adherent, so the cells were released by incubation
with trypsin-EDTA (0.05% trypsin, 0.53 mM EDTA). The
liberated cells were washed with phosphate-buffered saline,
centrifuged at 500  g, and whole-cell extract prepared by
sonication in WCL as described above. To prepare extract
under denaturing conditions, cells were harvested and the
cell pellet was resuspended in 1  Laemmli sample buffer
(Martin-Serrano et al., 2002) then immediately heated at
100°C for 3 min. The sample was cooled on ice and cen-
trifuged at 10,000  g to clear the lysate.
Synthesis of GST-Tat and P-TEFb kinase (TAK) assay
GST-Tat fusion proteins were produced in E. coli strain
BL21 by induction with 500 nM isopropyl--D-1-thioga-
lactopyranoside (IPTG) for 8 h at 30°C. Culture was har-
vested by centrifugation and cells lysed in EBCD (Tris-Cl,
pH 8.0, 50 mM, NaCl 120 mM, NP-40 0.5%, DTT 5 mM)
 1 mg/ml lysozyme followed by sonication. Cleared lysate
was produced by centrifugation at 10,000 rpm, 10 min at
4°C. This was incubated with 15 l of glutathione-Sepha-
rose 4B (AP Biotech, Uppsala, Sweden) for 1 h at 4°C with
rocking. For each reaction, approximately 2 g of GST-Tat
was bound to 15 l of glutathione beads. Beads were
washed five times with EBCD-SDSH (EBCD  0.075%
SDS), followed by four washes with EBCDMg (EBCD  4
mM MgCl2). Cell extract being assayed for P-TEFb kinase
activity was incubated with the beads for 2 h as before.
Beads were then washed five times with EBCD-SDSL
(EBCD 0.03% SDS) followed by three washes with TKB
(50 mM Tris-Cl, pH 7.6, 5 mM DTT, 5 mM MnCl2, 4 mM
MgCl2). Kinase reactions were carried out in a 40-l vol-
ume with the beads in TKB buffer with 10 Ci [32P]ATP,
2 M ATP, and 5 mM CTD3 or 1 g CTD4 at 25°C for 40
min. Reaction was terminated by the addition of 15 l of
4 Laemmli sample buffer and boiling. Reaction products
were resolved by SDS-polyacrylamide gel electrophoresis fol-
lowed by autoradiography.
Immunoblotting
Total protein in whole-cell extracts was quantified with
the Bio-Rad DC (Detergent Compatible) assay. Normalized
amounts of protein were incubated with GST-Tat-Sepharose
beads for 1 h in EBCDMg. Beads were then washed five
times with EBCD-SDSL (EBCD  0.03% SDS), boiled in
Laemmli sample buffer, and resolved in a SDS gel. The gel
was transferred by using a semidry transfer apparatus (Bio-
Rad) onto a 0.45 M nitrocellulose membrane (Schleicher
and Schuell, Keane, NH) and probed with primary antibody
(anti-cyclin T1 1:500, anti-CDK9 1:2000, anti-CDK7
1:1000, anti-CDK8 1:1000, anti-actin 1:20,000) and the
appropriate anti-goat or anti-rabbit lgG secondary horserad-
ish peroxidase-conjugated antibody.
Tat transactivation assays
For Tat transactivation in U937 cells, 1  107 cells were
electroporated in 250 l of RPMI 1640 at 250 V, 1100 F
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using a BTX (San Diego, CA) ECM 2001 electroporation
unit. Cells were cultured in 10 ml of media (RPMI 1640,
10% FBS) with 100 U/ml penicillin and 100 g/ml strep-
tomycin for 12 h. Cells were harvested by centrifugation at
500  g, washed with 10 ml of phosphate-buffered saline,
and lysed in 50 l of Promega Lysis Buffer. A dual lucif-
erase assay (Promega) was used to quantify Photinus pyra-
lis and Renilla neoformans luciferase expression in 20 l of
each sample in a luminometer (Packard, Meriden, CT).
Luciferase readings were always at least 10-fold above
background. For PMA treatment, cells were preincubated
for 12 h in RPMI 1640  10% FBS with PMA. Treated
cells became adherent and were collected by trypsinization.
Cells were counted and transfected as for untreated cells.
After transfection PMA treatment was continued for 12
additional hours and cells were collected by trypsinization.
Transfection in 293 cells was carried out in six-well plates
with Cytofectene reagent (Bio-Rad) according to the man-
ufacturer’s protocol. Cells were incubated for 24 h and
harvested by scraping in 200 l of Promega Lysis Buffer.
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